Securities Code: 301015 Bond Code: 123194 Securities Abbreviation: Baiyang Pharmaceutical Bond Abbreviation: Baiyang Convertible Bond Announcement Number: 2026-045
Qingdao Baiyang Pharmaceutical Co., Ltd. Announcement of Resolutions of the Eighth Meeting of the Fourth Board of Directors
The Company and all members of the Board of Directors guarantee the content of the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
I. Convening of the Board Meeting
The Eighth Meeting of the Fourth Board of Directors of Qingdao Baiyang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held in person and via communication on June 10, 2026. The meeting notice was sent to all directors via email on June 5, 2026. The meeting was convened and presided over by Mr. Fu Gang, Chairman of the Company. Nine directors were required to attend, and nine directors actually attended. The Company's General Manager and Secretary of the Board of Directors were present at the meeting. The convening of this meeting complies with relevant laws, administrative regulations, departmental rules, normative documents, and the "Articles of Association" of the Company. The resolutions of the meeting are legal and valid.
II. Deliberation of Board Meeting Resolutions
(I) Deliberated and approved the "Proposal on the Company's Issuance of H Share Stock and Listing on the Main Board of The Stock Exchange of Hong Kong Limited";
To further enhance the Company's capital strength and comprehensive competitiveness, deepen the Company's globalization strategy and overseas business layout, enhance brand influence and core competitiveness, consolidate its leading position in the industry, fully leverage the resources and institutional advantages of the international capital market, optimize its capital structure, broaden diversified financing channels, and comprehensively enhance the Company's overall strength, the Company plans to publicly issue H share stock (hereinafter referred to as "H shares") and list on the main board of The Stock Exchange of Hong Kong Limited (hereinafter referred to as "Hong Kong Stock Exchange") (hereinafter referred to as "this issuance and listing").
This issuance and listing by the Company will be conducted in accordance with the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Securities Law of the People's Republic of China" (hereinafter referred to as the "Securities Law"), the "Administrative Measures for the Trial Implementation of Securities and Listing of Domestic Enterprises Abroad" (hereinafter referred to as the "Administrative Measures for Overseas Listing"), the "Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited" (hereinafter referred to as the "Hong Kong Listing Rules"), and other relevant regulations, and will require approval or filing from the China Securities Regulatory Commission (hereinafter referred to as the "CSRC"), Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong (hereinafter referred to as the "SFC"), and other relevant government departments, regulatory authorities, and stock exchanges.
Resolution result: 9 votes in favor, 0 against, 0 abstentions. This proposal was submitted to the Board of Directors after deliberation by the Strategy Committee. This proposal is subject to shareholder approval.
(II) Deliberated and approved item by item the "Proposal on the Scheme for the Company's Issuance of H Share Stock and Listing on The Stock Exchange of Hong Kong Limited";
The specific scheme for this issuance and listing and the results of the item-by-item voting are as follows:
-
Listing Location The H share stock to be issued is intended to be listed on the main board of the Hong Kong Stock Exchange. Resolution result: 9 votes in favor, 0 against, 0 abstentions.
-
Type and Par Value of Shares to be Issued The shares to be issued are H shares to be listed on the main board of the Hong Kong Stock Exchange, all of which are ordinary shares, with a par value denominated in RMB, subscribed for in foreign currency, with a par value of RMB 1.00 per share. Resolution result: 9 votes in favor, 0 against, 0 abstentions.